AT-Patch (ATP-C130/ATP-C70) vs Cardio-TriTest

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AT-Patch (ATP-C130/ATP-C70)

by ATsens Co.

Cardio-TriTest

by Cardio-Phoenix

AI Verdict

AT-Patch is designed for extended, continuous ambulatory ECG monitoring, making it suitable for detecting intermittent arrhythmias and remote patient management. Cardio-TriTest, conversely, is an in-clinic diagnostic device that offers a multi-modal assessment (ECG, PCG, MCG) for comprehensive cardiovascular disease detection during a patient visit. While both leverage AI for cardiac analysis, their deployment and primary use cases are distinct.

Choose AT-Patch (ATP-C130/ATP-C70) if…

Choose AT-Patch if you require extended, continuous cardiac monitoring for patients in an ambulatory setting. Its 14-day wear time and shower-proof design make it ideal for detecting intermittent arrhythmias that might be missed during shorter in-clinic tests, allowing patients to maintain normal daily activities. The integrated AI analysis further supports efficient arrhythmia detection from the collected data.

View AT-Patch (ATP-C130/ATP-C70) →

Choose Cardio-TriTest if…

Choose Cardio-TriTest if your clinical setting requires a comprehensive, multi-modal cardiac assessment for immediate diagnostic insights. This 3-in-1 device, combining ECG, PCG, and MCG with AI-powered analysis, is best suited for primary care or cardiology practices aiming for earlier and more thorough detection of cardiovascular diseases during a single, non-invasive office visit.

View Cardio-TriTest →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AT-Patch (ATP-C130/ATP-C70)	Cardio-TriTest
Deployment	Wearable device for patients; analysis software deployed on-premise at medical institutions.	On-premise (device)
FDA Status	Cleared AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AT-Patch (ATP-C130/ATP-C70)

AT-Patch offers superior patient usability due to its wearable, compact, lightweight, and shower-proof design, allowing for up to 14 days of continuous monitoring without interruption to daily activities. It also includes a smartphone app for live ECG viewing and symptom recording, enhancing patient convenience.

Clinical Value

Cardio-TriTest

Cardio-TriTest, with its 3-in-1 diagnostic approach (ECG, PCG, MCG) and AI-powered analysis, provides a more comprehensive cardiovascular assessment for earlier and more thorough disease detection in primary care. Its related product, Cardio-HART, has strong clinical validation for detecting a broader range of conditions, including heart failure, valvular, and structural heart disease, offering 'echo-grade insights' at the point of care. While AT-Patch excels in long-term arrhythmia detection, Cardio-TriTest's multi-modal diagnostic scope offers a broader clinical utility for initial assessment.

Pricing & Value

Tie

Both AT-Patch and Cardio-TriTest lack publicly available pricing information, stating 'n/a' or 'contact for pricing.' Without transparent cost details, it is impossible to conduct a meaningful comparison of their pricing or assess which tool offers better value for money.

Enterprise Readiness

Cardio-TriTest

Cardio-TriTest explicitly states it is HIPAA compliant, and its related product, Cardio-HART, supports integration with major EHR systems via standard HL7 and FHIR protocols. While AT-Patch's software is compatible with Windows for on-premise deployment, its HIPAA compliance is only 'likely' and a Business Associate Agreement (BAA) is not explicitly mentioned, which is a critical component for enterprise adoption.

Innovation

Cardio-TriTest

Cardio-TriTest's integration of three distinct bio-signals (ECG, PCG, MCG) with AI for synchronized analysis and visual correlation represents a more significant innovation in comprehensive diagnostic methodology. This multi-modal approach aims to provide 'echo-equivalent findings' in a primary care setting, bridging a crucial diagnostic gap. While AT-Patch's extended wearable monitoring is innovative for patient convenience, Cardio-TriTest's fusion of diagnostic modalities offers a greater leap in diagnostic capability.

Support & Docs

AT-Patch (ATP-C130/ATP-C70)

AT-Patch provides readily accessible user manuals, quick guides, and catalogs through its online document center, indicating comprehensive support documentation for users. In contrast, specific support documentation for Cardio-TriTest is not readily available online beyond a general contact email, suggesting less transparent or accessible resources for users.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AT-Patch (ATP-C130/ATP-C70)	Cardio-TriTest
Product Name	AT-Patch (ATP-C130/ATP-C70)	Cardio-TriTest
Company	ATsens Co.	Cardio-Phoenix Inc.
Primary Diagnostic Modalities	Continuous ECG monitoring	3-in-1 diagnostic device (ECG, PCG, MCG)
AI-Powered Analysis	Integrated AI-powered analysis software for enhanced arrhythmia detection; AT-Report software with AI/machine learning algorithms for ECG analysis.	AI-powered analysis for heart disease detection.
Monitoring Duration / Type	Up to 14 days of continuous ECG monitoring (ATP-C130)	Point-in-time diagnostic test
Key Physical Attributes / Design	Wearable, compact and lightweight (13g), shower-proof design (IP57 for ATP-C130, IP44 for ATP-C70), no charging or electrode replacement required during monitoring.	Device-based, non-invasive test procedure.
Target Specialties	Cardiology, Family Medicine, Internal Medicine	Cardiology, Family Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring AT-Patch (ATP-C130/ATP-C70) and Cardio-TriTest.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a typical cardiology or primary care workflow, and for what specific clinical scenarios is each best suited?

AT-Patch is a wearable device for continuous cardiac monitoring for up to 14 days, ideal for detecting intermittent arrhythmias in an outpatient setting. Cardio-TriTest is an in-clinic diagnostic device that combines ECG, PCG, and MCG for a comprehensive, synchronized assessment of cardiovascular health during an office visit, aiding in earlier and more comprehensive disease detection.

What specific diagnostic insights do these tools offer beyond a standard ECG, and how do their AI capabilities enhance detection?

AT-Patch provides continuous ECG monitoring with AI/machine learning algorithms in its AT-Report software for enhanced arrhythmia detection over an extended period, utilizing a high-performance sensor chip to minimize motion artifact noise. Cardio-TriTest offers a 3-in-1 diagnostic, integrating 12-Lead ECG, 4 Lead Phonocardiograph (PCG), and 4 Lead Mechanocardiograph (MCG) to synchronize and visually correlate heart bio-signals, with AI-powered analysis for broader cardiovascular disease detection.

What are the key differences in patient experience and comfort between the AT-Patch wearable monitor and the Cardio-TriTest in-clinic diagnostic device?

Patients wearing the AT-Patch benefit from a compact (13g), lightweight, and shower-proof design that requires no charging or electrode replacement for up to 14 days, allowing for comfort and normal daily activities. The Cardio-TriTest involves a non-invasive, in-clinic test procedure, meaning the patient's experience is limited to the duration of the office visit for the diagnostic assessment.

What level of training and time commitment can a practice expect for staff to become proficient with each device and its associated software?

For AT-Patch, staff training would primarily focus on understanding the AT-Report software for AI-powered ECG analysis and managing the patient workflow for device application and data retrieval. For Cardio-TriTest, staff would require training on operating the 3-in-1 diagnostic device, performing the ECG, PCG, and MCG procedures, and interpreting the synchronized visual correlation of heart bio-signals provided by the AI-powered analysis.

How do the data analysis and reporting features of each tool support clinical decision-making, particularly regarding the visualization and interpretation of results?

AT-Patch's AT-Report software uses AI/machine learning algorithms to analyze continuous ECG data, generating reports for enhanced arrhythmia detection, and the AT-Note smartphone app allows patients to record symptoms for correlation. Cardio-TriTest offers synchronized bio-signal acquisition and visual correlation of ECG, PCG, and MCG data, with AI-powered analysis aiding in the interpretation of these combined signals for comprehensive cardiovascular disease detection.

What are the key considerations for rolling out each tool across multiple clinical sites or a larger healthcare system?

AT-Patch, as a wearable device, facilitates patient distribution across multiple sites, but its analysis software is deployed on-premise at medical institutions, requiring coordinated IT infrastructure at each location. Cardio-TriTest is a device-based solution for clinical settings, meaning each site would require its own physical device and trained personnel to operate it and perform the diagnostic procedures.